Report dashes hopes for new use for blockbuster weight-loss drug

Shares of Novo Nordisk plunged after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's disease failed to meet its main goal.

The company said the weight loss and diabetes treatment drug failed to show any significant reduction in the progression of Alzheimer's disease in patients.

Report dashes hopes for new use for blockbuster weight-loss drug